RBC Capital Rates Viridian Therapeutics (VRDN) buy

Analyst Lisa Walter reiterated her Buy rating and $35.00 price target on the biotech company as it advances its rare disease pipeline, a 86.27% upside from the current price.

By EarningsIQ Research Desk · Published Jun 30, 2026, 12:01 PM EDT · Updated Jul 1, 2026, 2:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

RBC Capital rated Viridian Therapeutics, Inc. ($VRDN) "buy" with a $35 price target on June 30, 2026.

Since the rating, $VRDN is up 11.4% after 1 week, up 8.3% after 1 month and up 3.6% to date (from the $18.37 close on Jun 30, 2026).

VRDN Viridian Therapeutics, Inc.

$19.03 -37.97% year to date

Daily close · Oct 16, 2026

Key Points

RBC Capital analyst Lisa Walter reiterated a Buy rating on Viridian Therapeutics with a $35.00 price target on June 30, 2026, suggesting significant upside from the current trading price of $18.79.
The stock is currently trading between its 52-week low of $13.18 and high of $34.29, sitting below its 50-day moving average of $21.66.
Wall Street sentiment remains largely positive with 16 analysts providing a mean price target of $36.63 for the Waltham-based biotechnology firm.

Get $VRDN trade alerts by text

We text you when insiders, Congress or big funds trade $VRDN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Viridian Therapeutics, Inc. alert may contain errors. Disclosures

On June 30, 2026, RBC Capital analyst Lisa Walter reiterated a Buy rating on Viridian Therapeutics, Inc. (VRDN + NasdaqCM), setting a price target of $35.00. This call comes as the company continues to push forward with its clinical pipeline for rare diseases. The $35.00 target reflects a belief in the long-term value of the firm's drug candidates compared to the current market price.

Analyst rating track record

RBC Capital vs. the S&P 500

YTD return +8.89% hypothetical

All-time return +12.74% S&P 500 +30.78%

vs. S&P 500 -18.04% behind the index

Hypothetical returns from RBC Capital's disclosed trades, not real profit or advice. How we model this.

Analysts Set New Price Targets

RBC Capital has been consistent in its coverage of the biotech firm throughout the summer. On the same day Lisa Walter reiterated her target, several other firms adjusted their views. Truist Securities maintained its Buy rating on June 30, 2026, and raised its price target from $35.00 to $38.00. Wedbush also stood out that day, maintaining an Outperform rating while aggressively lifting its target from $32.00 to $43.00. Needham stayed positive as well, keeping a Buy rating and nudging its target from $32.00 to $34.00. Earlier, on June 29, 2026, Wells Fargo upgraded the stock from a neutral stance to Overweight, raising its target to $31.00. More recently, on September 22, 2026, RBC Capital maintained an Outperform rating and increased its target to $38.00.

Viridian Stock Performance

Shares of Viridian Therapeutics were trading at $18.79 on Tuesday. The stock has seen a wide range over the last year, hitting a low of $13.18 and a high of $34.29. At its current price, the stock is trading below its 200-day moving average—a mathematical trend line of the last 200 closing prices—which sits at $23.36. The company has a market value of roughly $2.44 billion. With 16 analysts covering the stock, the consensus target price is $36.63, which is nearly double the current share price.

12-month forecast

$VRDN price target

Viridian Therapeutics, Inc. daily closes and this analyst's $35 target. Not advice.

Recent Financial Results

In its most recent reporting period, Viridian generated $71.13 million in revenue, which represents a growth rate of 2.79% over the previous year. The company is not yet profitable, reporting a loss of $3.40 per share. Because it is losing money as it spends on drug development, it does not have a meaningful P/E ratio, which is a common way to value a stock by comparing its price to its earnings. The company's return on equity—a measure of how effectively it uses investor money—is -0.66. Investors are looking toward November 5, 2026, when the company is expected to release its next set of financial results.

Focus on Rare Disease Treatments

Viridian Therapeutics is a biotechnology company that finds and develops treatments for serious and rare conditions. Its main focus is on thyroid eye disease (TED), a condition that causes inflammation and swelling around the eyes. The company is working on several different types of therapies, including some that can be injected under the skin rather than through an IV. These treatments aim to give patients more convenient options for managing their health. The firm also has projects targeting Graves' disease and other autoimmune issues.

What's Ahead for VRDN

The reiteration from RBC Capital serves as a reminder of the high stakes in the biotechnology sector, where stock prices often swing based on clinical trial news rather than immediate profits. While the $35.00 target shows confidence, the company's path depends heavily on the success of its upcoming trial data. Investors should note that analyst ratings are opinions and price targets are projections, not guarantees of future performance.